Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 14:15:1197513.
doi: 10.3389/fpsyt.2024.1197513. eCollection 2024.

Prevalence of somatic diseases in adults with attention deficit hyperactivity disorder in Japan is highest in people aged ≥40 years with mental disorders: a cross-sectional study of a Japanese health insurance claims database

Affiliations

Prevalence of somatic diseases in adults with attention deficit hyperactivity disorder in Japan is highest in people aged ≥40 years with mental disorders: a cross-sectional study of a Japanese health insurance claims database

Yoshikazu Takaesu et al. Front Psychiatry. .

Abstract

Introduction: Studies have reported an association between attention deficit hyperactivity disorder (ADHD) and somatic diseases; however, the correlation of mental disorders with the association between ADHD and somatic diseases remains uninvestigated. This study investigated and compared the prevalence of somatic diseases among adults with/without ADHD, stratified by the presence or absence of mental disorders.

Methods: This cross-sectional study (October 2020-September 2021), using data (June 2013-September 2021) from a Japanese health insurance claims database, included adult participants with a medical record of and receiving medication for ADHD (ADHD group); the control group (matched 1:5 by age/sex) comprised participants without ADHD. The prevalence and odds ratio (OR; ADHD versus control) of type 2 diabetes mellitus (T2DM), diabetes complications, hypertension, cardiovascular disease (CVD), dyslipidemia, gout and hyperuricemia, chronic obstructive pulmonary disease (COPD), non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH), and atopic dermatitis were investigated. Pooled ORs for stratified analysis were calculated using the Mantel-Haenszel method.

Results: In the matched analysis sets, the ORs for all somatic diseases were significantly higher for the ADHD group (n=15,028) versus the control group (n=74,796). On stratified analysis, the Mantel-Haenszel ORs were significant for NAFLD/NASH (1.53; 95% confidence interval [CI]: 1.34, 1.73), diabetes complications (1.39; 95% CI: 1.09, 1.77), and gout and hyperuricemia (1.34; 95% CI: 1.19, 1.51). Furthermore, the stratum-specific ORs for T2DM, hypertension, and dyslipidemia were >1 and <1 in the presence and absence of mental disorders, respectively. The prevalence of all somatic diseases except atopic dermatitis increased with age. For participants aged ≥40 years, the Mantel-Haenszel ORs were significant for all somatic diseases except CVD, COPD, and atopic dermatitis.

Conclusions: The prevalence of several somatic diseases, including chronic disorders, was high among adults with ADHD, particularly in those aged ≥40 years and those with mental disorders.

Keywords: Japan; attention deficit hyperactivity disorder; chronic diseases; health insurance claims database study; mental disorders; observational; somatic diseases; stratified analysis.

PubMed Disclaimer

Conflict of interest statement

YI and YS are employees of Shionogi & Co., Ltd. SI and HM are employees of Shionogi Pharmacovigilance Center Co., Ltd. PT is an employee of Takeda Pharmaceutical Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. This study received funding from Shionogi & Co., Ltd. and Takeda Pharmaceutical Co., Ltd. The funder had the following involvement with the study: the study design, collection, analysis, interpretation of data, the writing of this article and the decision to submit it for publication.

Figures

Figure 1
Figure 1
Study design. ADHD, attention deficit hyperactivity disorder.
Figure 2
Figure 2
Participant flowchart. ADHD, attention deficit hyperactivity disorder.
Figure 3
Figure 3
Somatic diseases stratified by the presence or absence of mental disorders (matched analysis set). *Odds ratio for the ADHD/control group in the matched analysis set, including stratification results. **P values in bold font were significant and rejected by the Breslow-Day test. The Mantel-Haenszel odds ratio (Mantel-Haenszel OR) was not indicated if rejected by the Breslow-Day test. ADHD, attention deficit hyperactivity disorder; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; N/A, not applicable; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; T2DM, type 2 diabetes mellitus.
Figure 4
Figure 4
Somatic diseases stratified by the presence or absence of mental disorders in the ≥40 years age category (matched analysis set). *Odds ratio for the ADHD/control group in the matched analysis set, including stratification results. ADHD, attention deficit hyperactivity disorder; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; OR, odds ratio; T2DM, type 2 diabetes mellitus.

Similar articles

Cited by

References

    1. Salvi V, Migliarese G, Venturi V, Rossi F, Torriero S, Viganò V, et al. . ADHD in adults: clinical subtypes and associated characteristics. Riv Psichiatr (2019) 54:84–9. doi: 10.1708/3142.31249 - DOI - PubMed
    1. Jensen PS, Martin D, Cantwell DP. Comorbidity in ADHD: implications for research, practice, and DSM-V. J Am Acad Child Adolesc Psychiatry (1997) 36:1065–79. doi: 10.1097/00004583-199708000-00014 - DOI - PubMed
    1. Naya N, Tsuji T, Nishigaki N, Sakai C, Chen Y, Jung S, et al. . The burden of undiagnosed adults with attention-deficit/hyperactivity disorder symptoms in Japan: a cross-sectional study. Cureus (2021) 13:e19615. doi: 10.7759/cureus.19615 - DOI - PMC - PubMed
    1. Faraone SV, Banaschewski T, Coghill D, Zheng Y, Biederman J, Bellgrove MA, et al. . The World Federation of ADHD International Consensus Statement: 208 evidence-based conclusions about the disorder. Neurosci Biobehav Rev (2021) 128:789–818. doi: 10.1016/j.neubiorev.2021.01.022 - DOI - PMC - PubMed
    1. Narishige R. Hyperactivity disorder (attention deficit/hyperactivity disorder ADHD). Jpn J Psychiatr Treat (2015) 44:567–72.

LinkOut - more resources